Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: Metaanalysis and examination of FDA safety reports

Annals of Oncology

Volumn 22, Issue 5, 2011, Pages 1170-1180

  Evens, A M ^a   Jovanovic, B D ^a,b   Su, Y C ^b   Raisch, D W ^c   Ganger, D ^a,d   Belknap, S M ^a,d   Dai, M S ^d   Chiu, B C C ^e   Finte, B ^a,d   Cheng, Y ^c   Chuang, S S ^f   Lee, M Y ^g   Chen, T Y ^h   Lin, S F ⁱ   Kuo, C Y ^j  

^a NORTHWESTERN UNIVERSITY   (United States)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c UNIVERSITY OF NEW MEXICO   (United States)

^d TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^e UNIVERSITY OF CHICAGO   (United States)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^g CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^h NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

ⁱ KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^j CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

more..

Author keywords

FDA; HBV reactivation; Hepatitis B virus; Non Hodgkin's lymphoma; Rituximab

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B CORE ANTIBODY; LAMIVUDINE; RITUXIMAB; TELBIVUDINE; TENOFOVIR;

ARTICLE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HEPATITIS B; HEPATITIS B VIRUS REACTIVATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LYMPHOPROLIFERATIVE DISEASE; META ANALYSIS; PLASMAPHERESIS; PRIORITY JOURNAL; SIDE EFFECT; SYSTEMATIC REVIEW; VIRUS REACTIVATION;

EID: 79551543248     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq583     Document Type: Article

References (70)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745.
2. Alter MJ. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 2003; 39 (Suppl 1): S64-S69.
3. Cheng AL, Hsiung CA, Su IJ et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003; 37: 1320-1328.
4. Markovic S, Drozina G, Vovk M, Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 1999; 46: 2925-2930.
5. Liang R, Lau GK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 1999; 17: 394-398.
6. Lok AS, Liang RH, Chiu EK et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-188.
7. Yeo W, Chan PK, Zhong S et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307.
8. Lee GW, Ryu MH, Lee JL et al. The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with non-Hodgkin's lymphoma who receive cytotoxic chemotherapy. J Korean Med Sci 2003; 18: 849-854.
9. Loomba R, Rowley A, Wesley R et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 519-528.
10. Li YH, He YF, Jiang WQ et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006; 106: 1320-1325.
11. Ziakas PD, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009; 94: 998-1005.
12. Yeo W, Chan PK, Ho WM et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004; 22: 927-934.
13. Kumagai K, Takagi T, Nakamura S et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 1997; 8 (Suppl 1): 107-109.
14. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-220.
15. Aksoy S, Harputluoglu H, Kilickap S et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007; 48: 1307-1312.
16. Westhoff TH, Jochimsen F, Schmittel A et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102: 1930.
17. Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268-276.
18. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344: 68-69.
19. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm166521.htm (14 August 2010, date last accessed).
20. Dai MS, Chao TY, Kao WY et al. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 2004; 83: 769-774.
21. Garcia-Rodriguez MJ, Canales MA, Hernandez-Maraver D, Hernandez-Navarro F. Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment? Am J Hematol 2008; 83: 673-675.
22. He YF, Li YH, Wang FH et al. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma. Ann Hematol 2008; 87: 481-485.
23. Perceau G, Diris N, Estines O et al. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 2006; 155: 1053-1056.
24. Yang SH, Kuo SH. Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma. Ann Hematol 2008; 87: 325-327.
25. Lovric S, Erdbruegger U, Kumpers P et al. Rituximab as rescue therapy in antineutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients. Nephrol Dial Transplant 2009; 24: 179-185.
26. Gossmann J, Scheuermann EH, Kachel HG et al. Reactivation of hepatitis B two years after rituximab therapy in a renal transplant patient with recurrent focal segmental glomerulosclerosis: a note of caution. Clin Transplant 2009; 23: 431-434.
27. Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 2009; 18: 427-436.
28. Baker RA, Pikalov A, Tran QV et al. Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event Database: a systematic Bayesian Signal Detection Analysis. Psychopharmacol Bull 2009; 42: 11-31.
29. Lehman HP, Chen J, Gould AL et al. An evaluation of computer-aided disproportionality analysis for post-marketing signal detection. Clin Pharmacol Ther 2007; 82: 173-180.
30. Niscola P, Del Principe MI, Maurillo L et al. Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy. Leukemia 2005; 19: 1840-1841.
31. Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005; 11: 189-191.
32. Law JK, Ho JK, Hoskins PJ et al. Fatal reactivation of hepatitis B postchemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005; 46: 1085-1089.
33. Sera T, Hiasa Y, Michitaka K et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 2006; 45: 721-724.
34. Ozgonenel B, Moonka D, Savasan S. Fulminant hepatitis B following rituximab therapy in a patient with Evans syndrome and large B-cell lymphoma. Am J Hematol 2006; 81: 302.
35. Yamagata M, Murohisa T, Tsuchida K et al. Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab. Leuk Lymphoma 2007; 48: 431-433.
36. Colson P, Borentain P, Coso D et al. Entecavir as a first-line treatment for HBV reactivation following polychemotherapy for lymphoma. Br J Haematol 2008; 143: 148-150.
37. Miyagawa M, Minami M, Fujii K et al. Molecular characterization of a variant virus that caused de novo hepatitis B without elevation of hepatitis B surface antigen after chemotherapy with rituximab. J Med Virol 2008; 80: 2069-2078.
38. Koo YX, Tan DS, Tan IB et al. Hepatitis B virus reactivation in a patient with resolved hepatitis B virus infection receiving maintenance rituximab for malignant B-cell lymphoma. Ann Intern Med 2009; 150: 655-656.
39. Tsutsumi Y, Tanaka J, Kawamura T et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 2004; 83: 58-60.
40. Law JK, Ali JA, Harrigan PR et al. Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient. Am J Hematol 2006; 81: 969-972.
41. Khaled Y, Hanbali A. Hepatitis B virus reactivation in a case of Waldenstrom's macroglobulinemia treated with chemotherapy and rituximab despite adefovir prophylaxis. Am J Hematol 2007; 82: 688.
42. Marino D, Boso C, Crivellari G et al. Fatal HBV-related liver failure during lamivudine therapy in a patient with non-Hodgkin's lymphoma. Tumori 2008; 94: 748-749.
43. Wasmuth JC, Fischer HP, Sauerbruch T, Dumoulin FL. Fatal acute liver failure due to reactivation of hepatitis B following treatment with fludarabine/cyclophosphamide/rituximab for low grade non-Hodgkin's lymphoma. Eur J Med Res 2008; 13: 483-486.
44. Dillon R, Hirschfield GM, Allison ME, Rege KP. Fatal reactivation of hepatitis B after chemotherapy for lymphoma. BMJ 2008; 337: a423.
45. Aomatsu T, Komatsu H, Yoden A et al. Fulminant hepatitis B and acute hepatitis B due to intrafamilial transmission of HBV after chemotherapy for non-Hodgkin's lymphoma in an HBV carrier. Eur J Pediatr 2010; 169: 167-171.
46. Hui CK, Cheung WW, Zhang HY et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 59-68.
47. Li JM, Wang L, Shen Y et al. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients. Ann Hematol 2007; 86: 639-645.
48. Targhetta C, Cabras MG, Mamusa AM et al. Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy. Haematologica 2008; 93: 951-952.
49. Yeo W, Chan TC, Leung NW et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-611.
50. Hanbali A, Khaled Y. Incidence of hepatitis B reactivation following Rituximab therapy. Am J Hematol 2009; 84: 195.
51. Fukushima N, Mizuta T, Tanaka M et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol 2009; 20: 2013-2017.
52. Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 2009; 90: 13-23.
53. Tsutsumi Y, Shigematsu A, Hashino S et al. Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin's lymphoma in Hokkaido. Ann Hematol 2009; 88: 375-377.
54. Wang F, Xu RH, Luo HY et al. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC Cancer 2008; 8: 115.
55. Shih LN, Sheu JC, Wang JT et al. Serum hepatitis B virus DNA in healthy HBsAgnegative Chinese adults evaluated by polymerase chain reaction. J Med Virol 1990; 32: 257-260.
56. Carson KR, Evens AM, Richey EA et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113: 4834-4840.
57. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108810.htm (14 August 2010, date last accessed).
58. Bouaziz JD, Yanaba K, Venturi GM et al. Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc Natl Acad Sci USA 2007; 104: 20878-20883.
59. Stasi R, Del Poeta G, Stipa E et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007; 110: 2924-2930.
60. Marzano A, Angelucci E, Andreone P et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007; 39: 397-408.
61. Pei SN, Chen CH, Lee CM et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010; 89: 255-262.
62. Lubel JS, Testro AG, Angus PW. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J 2007; 37: 705-712.
63. Schnepf N, Sellier P, Bendenoun M et al. Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy. J Clin Virol 2007; 39: 48-50.
64. Hui CK, Sun J, Au WY et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol 2005; 42: 813-819.
65. Wang JT, Wang TH, Sheu JC et al. Detection of hepatitis B virus DNA by polymerase chain reaction in plasma of volunteer blood donors negative for hepatitis B surface antigen. J Infect Dis 1991; 163: 397-399.
66. Ludwig E, Mendelsohn RB, Taur Y et al. Prevalence of hepatitis B surface antigen and hepatitis B core antibody in a population initiating immunosuppressive therapy. J Clin Oncol 2005; 28: 9008a.
67. Hwang J, Fisch M, Zhang H et al. Hepatitis B screening and positivity prior to chemotherapy. J Clin Oncol 2010; 28: 9009a.
68. Gordan LN, Grow WB, Pusateri A et al. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 2005; 23: 1096-1102.
69. Hsieh CY, Huang HH, Lin CY et al. Rituximab-induced hepatitis C virus reactivation after spontaneous remission in diffuse large B-cell lymphoma. J Clin Oncol 2008; 26: 2584-2586.
70. Ollier L, Tieulie N, Sanderson F et al. Chronic hepatitis after hepatitis E virus infection in a patient with non-Hodgkin lymphoma taking rituximab. Ann Intern Med 2009; 150: 430-431.